Full history for every metric is available with a Kvantra account
Xylo Technologies Ltd. (XYLO)
Key financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 1 | 10 | 92 | 92 | 30 | 30 |
| Operating profit | $m | -8 | -8 | |||||
| Net profit | $m | -14 | -4 | 7 | -10 | -16 | -6 | -6 |
| EPS reported | $ | -8.36 | -8.58 | |||||
| Operating cashflow per share | $ | -2.53 | -2.53 | |||||
| Capex per share | $ | 0.02 | 0.02 | |||||
| FCF per share | $ | -2.55 | -2.55 | |||||
| Free cash flow | $m | -2 | -2 | |||||
| Net debt | $m | -8 | -8 | |||||
| Book value equity | $m | 18 | 18 | |||||
| Book value per share | $ | 24.95 | 23.45 | |||||
| Number of shares | m | 0.72 | 0.77 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 0.15 | 0.21 | |||||
| P/S LTM | x | 0.09 | 0.13 | |||||
| P/FCF LTM | x | -1.42 | -2.05 | |||||
| EV/EBITDA LTM | x | -0.10 | 0.84 | |||||
| EV/Sales LTM | x | 0.02 | -0.14 | |||||
| Earnings Yield LTM | % | -230.97% | -164.92% | |||||
| FCF Yield | % | -70.36% | -48.68% | |||||
| Quality | ||||||||
| ROE | % | -33.51% | -29.00% | |||||
| ROIC | % | -30.79% | -30.79% | |||||
| Operating margin | % | -26.85% | -26.85% | |||||
| Gross margin | % | 22.38% | 22.38% | |||||
| FCF/Sales | % | -6.15% | -6.15% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -67.45% | -67.45% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -0.27 | -0.27 | |||||
| Net Debt/EBITDA | x | 0.25 | 0.25 | |||||
| EBIT/Net interest | x | -7.63 | -7.63 | |||||
| Net debt/market cap | % | -299.23% | -207.02% | |||||
| Net debt/Equity | x | -0.43 | -0.43 | |||||
| Gross debt/equity | x | 0.38 | 0.38 | |||||
Company overview
Operating from its Tel Aviv-Yafo, Israel headquarters since its establishment in 1999, Xylo Technologies Ltd. is a technology company with a broad international presence, serving markets in the United States, Europe, Asia, and Israel. The company's diverse operations are categorized into Corporate, E-commerce, Online Advertising & Internet Traffic Routing, Online Event Management, and Other segments. In the medical field, Xylo Technologies develops and supplies devices such as the Medigus Ultrasonic Surgical Endostapler, an endoscopy system specifically designed for treating gastroesophageal reflux disease, alongside biological gels engineered to defend against biological hazards and minimize the entry of allergens and viruses through the upper airways and eyes. Beyond healthcare, its ventures extend to providing a digital advertising platform, managing online retail stores that sell various consumer items on the Amazon marketplace, and running an online platform for event organization and ticket sales. Furthermore, Xylo Technologies is involved in pioneering wireless electric vehicle charging solutions and advanced modular electronic vehicle designs. The company, previously known as Medigus Ltd., adopted its current name in April 2024.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Xylo Technologies Ltd. (XYLO)
Operating from its Tel Aviv-Yafo, Israel headquarters since its establishment in 1999, Xylo Technologies Ltd. is a technology company with a broad international presence, serving markets in the United States, Europe, Asia, and Israel. The company's diverse operations are categorized into Corporate, E-commerce, Online Advertising & Internet Traffic Routing, Online Event Management, and Other segments. In the medical field, Xylo Technologies develops and supplies devices such as the Medigus Ultrasonic Surgical Endostapler, an endoscopy system specifically designed for treating gastroesophageal reflux disease, alongside biological gels engineered to defend against biological hazards and minimize the entry of allergens and viruses through the upper airways and eyes. Beyond healthcare, its ventures extend to providing a digital advertising platform, managing online retail stores that sell various consumer items on the Amazon marketplace, and running an online platform for event organization and ticket sales. Furthermore, Xylo Technologies is involved in pioneering wireless electric vehicle charging solutions and advanced modular electronic vehicle designs. The company, previously known as Medigus Ltd., adopted its current name in April 2024.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free